Publications by authors named "Jonathan Doty"

Claim this Profile
O
Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.
Ryan P Moenster, Ashleigh Wallace-Lacey, Hannah Western, Seth Tiefenaur, Anosha Abdulbasir, Jonathan Doty

Open Forum Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration.
Smathorn Thakolwiboon, Elizabeth A Mills, Jennifer Yang, Jonathan Doty, Martin I Belkin

Front Aging· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
Justin I Montgomery, Matthew F Brown, Usa Reilly, Loren M Price, Joseph A Abramite, Jonathan Doty

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent inhibitors of LpxC for the treatment of Gram-negative infections.
Matthew F Brown, Usa Reilly, Joseph A Abramite, Joel T Arcari, Robert Oliver, Jonathan Doty

J Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Mark E Flanagan, Todd A Blumenkopf, William H Brissette, Matthew F Brown, Jeffrey M Casavant, Jonathan L Doty

J Med Chem· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor.
Amy S Antipas, Laura C Blumberg, William H Brissette, Matthew F Brown, Jeffrey M Casavant, Jonathan L Doty

Bioorg Med Chem Lett· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of orally bioavailable thrombopoietin agonists.
Michael J Munchhof, Amy S Antipas, Laura C Blumberg, William H Brissette, Matthew F Brown, Jonathan L Doty

Bioorg Med Chem Lett· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The specificity of JAK3 kinase inhibitors.
Paul S Changelian, Deborah Moshinsky, Cyrille F Kuhn, Mark E Flanagan, Michael J Munchhof, Jonathan L Doty

Blood· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrimidine benzamide-based thrombopoietin receptor agonists.
Lawrence A Reiter, Chakrapani Subramanyam, Emilio J Mangual, Christopher S Jones, Marc I Smeets, Jonathan L Doty

Bioorg Med Chem Lett· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of unknown primary carcinomas metastatic to the neck: diagnosis, treatment, and outcomes.
Jonathan M Doty, David Gossman, Mahesh Kudrimoti, Joseph Valentino, Susanne Arnold

J Ky Med Assoc· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomechanical evaluation of fixation techniques for bridging segmental mandibular defects.
Jonathan M Doty, David Pienkowski, Michele Goltz, Richard H Haug, Joseph Valentino

Arch Otolaryngol Head Neck Surg· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.
Michael J Munchhof, Jean S Beebe, Jeffery M Casavant, Beth A Cooper, Jonathan L Doty

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis